Back to News
Market Impact: 0.25
Scholar Rock Resubmits Marketing Authorisation Application For Apitegromab
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Scholar Rock resubmitted its Marketing Authorisation Application for apitegromab to the European Medicines Agency, seeking authorization to treat children and adults with spinal muscular atrophy. The available article text ends while describing an alternate fill-related component of the resubmission; it reports no regulatory decision.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
SRRK0.55
More News
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- SpaceX to buy key spectrum that could help Starlink Mobile become major US cell carrier
- Why is the Chinese stock market missing the AI rally
- ‘Piece by piece’: Trump administration vows to dismantle the International Criminal Court with sweeping new sanctions
- Why is T-Mobile stock tumbling today?